Lars Rebien Sørensen, CEO of Novo Nordisk, discusses his company's earnings guidance and strong half year growth, as well as its strategy in China.
The federal government says health care facilities should stop using Hospira's Symbiq medication infusion pump because its vulnerable to hacking.
The CEO of Medtronic talks new FDA approval and how to improve the health-care system.
Mount Sinai's CEO sees a "death spiral" could occur if the Supreme Court rules against the health insurance subsidies in Obamacare.
Bad news has been a boon for Malaysia's rubber glove makers, with the ringgit's drop and South Korea's MERS outbreak likely to provide a twin boost.
There have only been four flu pandemics since the start of the 20th century, yet concerns are widening about the potential for a new outbreak.
Cathrin Petty, co-head of EMEA healthcare at JP Morgan, says the U.K. has the capacity to be a successful market for life sciences, and the year ahead for healthcare IPOs looks strong.
George Freeman MP, minister of life sciences in the U.K., says there's been a "resurgence" for life sciences and healthcare investment.
How much would it cost world governments to insulate their economies from global pandemics. Would you believe nearly $344 billion?
A flu shot that lasts 10 years could be a reality soon, a top hospital executive told CNBC, along with "real steps" toward a cancer vaccine.
Two young engineers invented a product that uses LED lights to fight bacteria and decrease risk of infections in hospitals and public spaces.
Health care has been on a tear in 2014, and there is still room for upside. Wall Street analysts are focusing on the following four trends.
Dr. Louis Sullivan, former HHS Secretary, discusses President Obama's decision to send 3,000 U.S. troops to West Africa to help in their fight with Ebola.
Ebola outbreaks may become more frequent because of climate change, scientists warn, as the deadly disease ravages West Africa.
Shares of Malaysia's latex glove makers have had a tough year so far, but some analysts expect panic over Africa's Ebola outbreak may spur gains.
Lawrence Livermore is reaching out to private industry amid a race for talent and ideas to solve pressing issues including national security.
CRE, one of the worst of the superbugs, is spreading in some hospitals, and there's worry that cases are under-reported.
As AstraZeneca's shares slid following its rejection of Pfizer's new bid, the company's chairman said he was "reasonably confident" it was the right decision.
Johnson & Johnson turned in a solid first quarter Tuesday, topping analysts' profit and revenue estimates and increasing its 2014 earnings forecast by 5 cents a share.
As healthcare reform begins to take shape, venture capitalists see emerging opportunities in digital health start-ups.